Abstract
Epidemiological studies have provided the evidence for association between nephrolithiasis and a number of cardiovascular diseases including hypertension, diabetes, chronic kidney disease, metabolic syndrome. Many of the co-morbidities may not only lead to stone disease but also be triggered by it. Nephrolithiasis is a risk factor for development of hypertension and have higher prevalence of diabetes mellitus and some hypertensive and diabetic patients are at greater risk for stone formation. An analysis of the association between stone disease and other simultaneously appearing disorders, as well as factors involved in their pathogenesis, may provide an insight into stone formation and improved therapies for stone recurrence and prevention. It is our hypothesis that association between stone formation and development of co-morbidities is a result of certain common pathological features. Review of the recent literature indicates that production of reactive oxygen species (ROS) and development of oxidative stress (OS) may be such a common pathway. OS is a common feature of all cardiovascular diseases (CVD) including hypertension, diabetes mellitus, atherosclerosis and myocardial infarct. There is increasing evidence that ROS are also produced during idiopathic calcium oxalate (CaOx) nephrolithiasis. Both tissue culture and animal model studies demonstrate that ROS are produced during interaction between CaOx/calcium phosphate (CaP) crystals and renal epithelial cells. Clinical studies have also provided evidence for the development of oxidative stress in the kidneys of stone forming patients. Renal disorders which lead to OS appear to be a continuum. Stress produced by one disorder may trigger the other under the right circumstances.
Similar content being viewed by others
References
Pearle MS, Calhoun EA, Curhan GC (2005) Urologic diseases in America project: urolithiasis. J Urol 173:848
Stamatelou KK, Francis ME, Jones CA et al (2003) Time trends in reported prevalence of kidney stones in the United States: 1976–1994. Kidney Int 63:1817
Soucie JM, Coates RJ, McClellan W et al (1996) Relation between geographic variability in kidney stones prevalence and risk factors for stones. Am J Epidemiol 143:487
Brikowski TH, Lotan Y, Pearle MS (2008) Climate-related increase in the prevalence of urolithiasis in the United States. Proc Natl Acad Sci USA 105:9841
Obligado SH, Goldfarb DS (2008) The association of nephrolithiasis with hypertension and obesity: a review. Am J Hypertens 21:257
Lieske JC, de la Vega LS, Gettman MT et al (2006) Diabetes mellitus and the risk of urinary tract stones: a population-based case–control study. Am J Kidney Dis 48:897
Jeong IG, Kang T, Bang JK et al (2011) Association between metabolic syndrome and the presence of kidney stones in a screened population. Am J Kidney Dis 58:383
Saucier NA, Sinha MK, Liang KV et al (2009) Risk factors for CKD in persons with kidney stones: a case-control study in Olmsted County, Minnesota. Am J Kidney Dis 55:61
Coe FL, Evan AP, Worcester EM et al (2010) Three pathways for human kidney stone formation. Urol Res 38:147
Johri N, Cooper B, Robertson W et al (2010) An update and practical guide to renal stone management. Nephron Clin Pract 116:c159
Tibblin G (1965) A population study of 50-year-old men. An analysis of the non-participation group. Acta Med Scand 178:453
Cirillo M, Laurenzi M (1988) Elevated blood pressure and positive history of kidney stones: results from a population-based study. J Hypertens Suppl 6:S485
Cappuccio FP, Strazzullo P, Mancini M (1990) Kidney stones and hypertension: population based study of an independent clinical association. BMJ 300:1234
Kim YJ, Park MS, Kim WT et al (2010) Hypertension influences recurrent stone formation in nonobese stone formers. Urology 77:1059
Cappuccio FP, Siani A, Barba G et al (1999) A prospective study of hypertension and the incidence of kidney stones in men. J Hypertens 17:1017
Strazzullo P, Barba G, Vuotto P et al (2001) Past history of nephrolithiasis and incidence of hypertension in men: a reappraisal based on the results of the Olivetti Prospective Heart Study. Nephrol Dial Transplant 16:2232
Madore F, Stampfer MJ, Rimm EB et al (1998) Nephrolithiasis and risk of hypertension. Am J Hypertens 11:46
Madore F, Stampfer MJ, Willett WC et al (1998) Nephrolithiasis and risk of hypertension in women. Am J Kidney Dis 32:802
Borghi L, Meschi T, Guerra A et al (1999) Essential arterial hypertension and stone disease. Kidney Int 55:2397
Stoller ML, Low RK, Shami GS et al (1996) High resolution radiography of cadaveric kidneys: unraveling the mystery of Randall’s plaque formation. J Urol 156:1263
Wexler BC, McMurtry JP (1981) Kidney and bladder calculi in spontaneously hypertensive rats. Br J Exp Pathol 62:369
Koletsky S (1975) Pathologic findings and laboratory data in a new strain of obese hypertensive rats. Am J Pathol 80:129
Domingos F, Serra A (2010) Nephrolithiasis is associated with an increased prevalence of cardiovascular disease. Nephrol Dial Transplant 26:864
Akoudad S, Szklo M, McAdams MA et al (2010) Correlates of kidney stone disease differ by race in a multi-ethnic middle-aged population: the ARIC study. Prev Med 51:416
Gillen DL, Coe FL, Worcester EM (2005) Nephrolithiasis and increased blood pressure among females with high body mass index. Am J Kidney Dis 46:263
Breslau NA, Pak CY (1982) Endocrine aspects of nephrolithiasis. Spec Top Endocrinol Metab 3:57
Liu JG, Hu M, He XQ (1989) Risk factors for the formation of urinary calcium-containing stones in diabetics. Zhonghua Nei Ke Za Zhi 28:649
Meydan N, Barutca S, Caliskan S et al (2003) Urinary stone disease in diabetes mellitus. Scand J Urol Nephrol 37:64
Taylor EN, Stampfer MJ, Curhan GC (2005) Diabetes mellitus and the risk of nephrolithiasis. Kidney Int 68:1230
Pak CY, Sakhaee K, Moe O et al (2003) Biochemical profile of stone-forming patients with diabetes mellitus. Urology 61:523
Daudon M, Traxer O, Conort P et al (2006) Type 2 diabetes increases the risk for uric acid stones. J Am Soc Nephrol 17:2026
Zimmerer T, Weiss C, Hammes HP et al (2009) Evaluation of urolithiasis: a link between stone formation and diabetes mellitus? Urol Int 82:350
Eisner BH, Porten SP, Bechis SK et al (2010) Diabetic kidney stone formers excrete more oxalate and have lower urine pH than nondiabetic stone formers. J Urol 183:2244
Hamano S, Nakatsu H, Suzuki N et al (2005) Kidney stone disease and risk factors for coronary heart disease. Int J Urol 12:859
Ljunghall S, Hedstrand H (1976) Renal stones and coronary heart disease. Acta Med Scand 199:481
Rule AD, Bergstralh EJ, Melton LJ 3rd et al (2009) Kidney stones and the risk for chronic kidney disease. Clin J Am Soc Nephrol 4:804
Rule AD, Roger VL, Melton LJ 3rd et al (2010) Kidney stones associate with increased risk for myocardial infarction. J Am Soc Nephrol 21:1641
Reiner AP, Kahn A, Eisner BH et al (2011) Kidney stones and subclinical atherosclerosis in young adults: the CARDIA study. J Urol 185:920
Gupta M, Bolton DM, Gupta PN et al (1994) Improved renal function following aggressive treatment of urolithiasis and concurrent mild to moderate renal insufficiency. J Urol 152:1086
Goel MC, Ahlawat R, Kumar M et al (1997) Chronic renal failure and nephrolithiasis in a solitary kidney: role of intervention. J Urol 157:1574
Gillen DL, Worcester EM, Coe FL (2005) Decreased renal function among adults with a history of nephrolithiasis: a study of NHANES III. Kidney Int 67:685
Vupputuri S, Soucie JM, McClellan W et al (2004) History of kidney stones as a possible risk factor for chronic kidney disease. Ann Epidemiol 14:222
Ingsathit A, Thakkinstian A, Chaiprasert A et al (2010) Prevalence and risk factors of chronic kidney disease in the Thai adult population: Thai SEEK study. Nephrol Dial Transplant 25:1567
Meneses JA, Lucas FM, Assuncao FC et al (2011) The impact of metaphylaxis of kidney stone disease in the renal function at long term in active kidney stone formers patients. Urol Res [Epub ahead of print]
Dandona P, Aljada A, Chaudhuri A et al (2005) Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 111:1448
Curhan GC, Willett WC, Rimm EB et al (1998) Body size and risk of kidney stones. J Am Soc Nephrol 9:1645
Taylor EN, Stampfer MJ, Curhan GC (2005) Obesity, weight gain, and the risk of kidney stones. JAMA 293:455
West B, Luke A, Durazo-Arvizu RA et al (2008) Metabolic syndrome and self-reported history of kidney stones: the National Health and Nutrition Examination Survey (NHANES III) 1988–1994. Am J Kidney Dis 51:741
Ando R, Suzuki S, Nagaya T et al (2011) Impact of insulin resistance, insulin and adiponectin on kidney stones in the Japanese population. Int J Urol 18:131
Ferder L, Ferder MD, Inserra F (2010) The role of high-fructose corn syrup in metabolic syndrome and hypertension. Curr Hypertens Rep 12:105
Jalal DI, Smits G, Johnson RJ et al (2010) Increased fructose associates with elevated blood pressure. J Am Soc Nephrol 21:1543
Taylor EN, Curhan GC (2008) Fructose consumption and the risk of kidney stones. Kidney Int 73:207
Robertson WG (2003) A risk factor model of stone-formation. Front Biosci 8:s1330
Kok DJ, Khan SR (1994) Calcium oxalate nephrolithiasis, a free or fixed particle disease. Kidney Int 46:847
Khan SR, Kok DJ (2004) Modulators of urinary stone formation. Front Biosci 9:1450
Cameron MA, Maalouf NM, Adams-Huet B et al (2006) Urine composition in type 2 diabetes: predisposition to uric acid nephrolithiasis. J Am Soc Nephrol 17:1422
Strazzullo P, Mancini M (1994) Hypertension, calcium metabolism, and nephrolithiasis. Am J Med Sci 307(Suppl 1):S102
Timio F, Kerry SM, Anson KM et al (2003) Calcium urolithiasis, blood pressure and salt intake. Blood Press 12:122
Taylor EN, Curhan GC (2006) Body size and 24-hour urine composition. Am J Kidney Dis 48:905
Mente A, Honey RJ, McLaughlin JM et al (2006) High urinary calcium excretion and genetic susceptibility to hypertension and kidney stone disease. J Am Soc Nephrol 17:2567
Schleicher MM, Reis MC, Costa SS et al (2009) Patients with nephrolithiasis and blood hypertension have higher calciuria than those with isolated nephrolithiasis or hypertension? Minerva Urol Nefrol 61:9
Eisner BH, Porten SP, Bechis SK et al (2010) Hypertension is associated with increased urinary calcium excretion in patients with nephrolithiasis. J Urol 183:576
Taylor EN, Mount DB, Forman JP et al (2006) Association of prevalent hypertension with 24-hour urinary excretion of calcium, citrate, and other factors. Am J Kidney Dis 47:780
Maalouf NM, Cameron MA, Moe OW et al (2010) Metabolic basis for low urine pH in type 2 diabetes. Clin J Am Soc Nephrol 5:1277
Randall A (1937) The origin and growth of renal calculi. Ann Surg 105:1009
Carpentier X, Bazin D, Jungers P et al (2010) The pathogenesis of Randall’s plaque: a papilla cartography of Ca compounds through an ex vivo investigation based on XANES spectroscopy. J Synchrotron Radiat 17:374
Khan SR, Finlayson B, Hackett R (1984) Renal papillary changes in patient with calcium oxalate lithiasis. Urology 23:194
Evan AP, Lingeman JE, Coe FL et al (2003) Randall’s plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J Clin Invest 111:607
Weller RO, Nester B, Cooke SAR (1971) Calcification in the human renal papilla: an electron microscope study. J Pathol 107:211
Stoller ML, Meng MV, Abrahams HM et al (2004) The primary stone event: a new hypothesis involving a vascular etiology. J Urol 171:1920
Miller NL, Gillen DL, Williams JC Jr et al (2009) A formal test of the hypothesis that idiopathic calcium oxalate stones grow on Randall’s plaque. BJU Int 103:966
Coe FL, Evan AP, Lingeman JE et al (2010) Plaque and deposits in nine human stone diseases. Urol Res 38:239
Evan AP, Lingeman JE, Coe FL et al (2008) Role of interstitial apatite plaque in the pathogenesis of the common calcium oxalate stone. Semin Nephrol 28:111
Evan AP (2009) Physiopathology and etiology of stone formation in the kidney and the urinary tract. Pediatr Nephrol 25:831
Evan AP, Coe FL, Rittling SR et al (2005) Apatite plaque particles in inner medulla of kidneys of calcium oxalate stone formers: osteopontin localization. Kidney Int 68:145
Evan AP, Bledsoe S, Worcester EM et al (2007) Renal inter-alpha-trypsin inhibitor heavy chain 3 increases in calcium oxalate stone-forming patients. Kidney Int 72:1503
Evan A, Lingeman J, Coe FL et al (2006) Randall’s plaque: pathogenesis and role in calcium oxalate nephrolithiasis. Kidney Int 69:1313
Haggit RC, Pitcock JA (1971) Renal medullary calcification: a light and electron microscopic study. J Urol 106:342
Cooke SAR (1970) The site of calcification in the human renal papilla. Br J Surg 57:890
Carpentier X, Bazin D, Combes C et al (2011) High Zn content of Randall’s plaque: a mu-X-ray fluorescence investigation. J Trace Elem Med Biol 25:160
Khan SR (2004) Crystal-induced inflammation of the kidneys: results from human studies, animal models, and tissue-culture studies. Clin Exp Nephrol 8:75
Gower LB (2008) Biomimetic model systems for investigating the amorphous precursor pathway and its role in biomineralization. Chem Rev 108:4551
Murshed M, McKee MD (2010) Molecular determinants of extracellular matrix mineralization in bone and blood vessels. Curr Opin Nephrol Hypertens 19:359
Baggio B, Gambaro G, Ossi E et al (1983) Increased urinary excretion of renal enzymes in idiopathic calcium oxalate nephrolithiasis. J Urol 129:1161
Huang HS, Ma MC, Chen CF et al (2003) Lipid peroxidation and its correlations with urinary levels of oxalate, citric acid, and osteopontin in patients with renal calcium oxalate stones. Urology 62:1123
Tungsanga K, Sriboonlue P, Futrakul P et al (2005) Renal tubular cell damage and oxidative stress in renal stone patients and the effect of potassium citrate treatment. Urol Res 33:65
Boonla C, Wunsuwan R, Tungsanga K et al (2007) Urinary 8-hydroxydeoxyguanosine is elevated in patients with nephrolithiasis. Urol Res 35:185
Tsao KC, Wu TL, Chang PY et al (2007) Multiple risk markers for atherogenesis associated with chronic inflammation are detectable in patients with renal stones. J Clin Lab Anal 21:426
Mushtaq S, Siddiqui AA, Naqvi ZA et al (2007) Identification of myeloperoxidase, alpha-defensin and calgranulin in calcium oxalate renal stones. Clin Chim Acta 384:41
Taylor EN, Fung TT, Curhan GC (2009) DASH-style diet associates with reduced risk for kidney stones. J Am Soc Nephrol 20:2253
Evan AP, Coe FL, Lingeman JE et al (2006) Renal crystal deposits and histopathology in patients with cystine stones. Kidney Int 69:2227
Evan AP, Lingeman J, Coe F et al (2007) Renal histopathology of stone-forming patients with distal renal tubular acidosis. Kidney Int 71:795
Evan AP, Lingeman JE, Coe FL et al (2005) Crystal-associated nephropathy in patients with brushite nephrolithiasis. Kidney Int 67:576
Evan AP, Lingeman JE, Worcester EM et al (2010) Renal histopathology and crystal deposits in patients with small bowel resection and calcium oxalate stone disease. Kidney Int 78:310
Evan AP, Coe FL, Gillen D et al (2008) Renal intratubular crystals and hyaluronan staining occur in stone formers with bypass surgery but not with idiopathic calcium oxalate stones. Anat Rec (Hoboken) 291:325
Evan AE, Lingeman JE, Coe FL et al (2008) Histopathology and surgical anatomy of patients with primary hyperparathyroidism and calcium phosphate stones. Kidney Int 74:223
Escobar C, Byer KJ, Khaskheli H et al (2008) Apatite induced renal epithelial injury: insight into the pathogenesis of kidney stones. J Urol 180:379
Aihara K, Byer KJ, Khan SR (2003) Calcium phosphate-induced renal epithelial injury and stone formation: involvement of reactive oxygen species. Kidney Int 64:1283
Umekawa T, Byer K, Uemura H et al (2005) Diphenyleneiodium (DPI) reduces oxalate ion- and calcium oxalate monohydrate and brushite crystal-induced upregulation of MCP-1 in NRK 52E cells. Nephrol Dial Transplant 20:870
Umekawa T, Chegini N, Khan SR (2003) Increased expression of monocyte chemoattractant protein-1 (MCP-1) by renal epithelial cells in culture on exposure to calcium oxalate, phosphate and uric acid crystals. Nephrol Dial Transplant 18:664
Giachelli CM (2005) Inducers and inhibitors of biomineralization: lessons from pathological calcification. Orthod Craniofac Res 8:229
Thamilselvan S, Hackett RL, Khan SR (1997) Lipid peroxidation in ethylene glycol induced hyperoxaluria and calcium oxalate nephrolithiasis. J Urol 157:1059
Thamilselvan S, Hackett RL, Khan SR (1999) Cells of proximal and distal tubular origin respond differently to challenges of oxalate and calcium oxalate crystals. J Am Soc Nephrol 10(Suppl 14):S452
Khan SR (2005) Hyperoxaluria-induced oxidative stress and antioxidants for renal protection. Urol Res 33:349
Khan SR, Glenton PA, Byer KJ (2006) Modeling of hyperoxaluric calcium oxalate nephrolithiasis: experimental induction of hyperoxaluria by hydroxy-l-proline. Kidney Int 70:914
Khan SR (1995) Calcium oxalate crystal interaction with renal tubular epithelium, mechanism of crystal adhesion and its impact on stone development. Urol Res 23:71
Sumitra K, Pragasam V, Sakthivel R et al (2005) Beneficial effect of vitamin E supplementation on the biochemical and kinetic properties of Tamm–Horsfall glycoprotein in hypertensive and hyperoxaluric patients. Nephrol Dial Transplant 20:1407
Huang HS, Chen J, Chen CF et al (2006) Vitamin E attenuates crystal formation in rat kidneys: roles of renal tubular cell death and crystallization inhibitors. Kidney Int 70:699
Thamilselvan S, Byer KJ, Hackett RL et al (2000) Free radical scavengers, catalase and superoxide dismutase provide protection from oxalate-associated injury to LLC-PK1 and MDCK cells. J Urol 164:224
Thamilselvan S, Khan SR, Menon M (2003) Oxalate and calcium oxalate mediated free radical toxicity in renal epithelial cells: effect of antioxidants. Urol Res 31:3
Khand FD, Gordge MP, Robertson WG et al (2002) Mitochondrial superoxide production during oxalate-mediated oxidative stress in renal epithelial cells. Free Radic Biol Med 32:1339
Meimaridou E, Jacobson J, Seddon AM et al (2005) Crystal and microparticle effects on MDCK cell superoxide production: oxalate-specific mitochondrial membrane potential changes. Free Radic Biol Med 38:1553
Cao LC, Honeyman TW, Cooney R et al (2004) Mitochondrial dysfunction is a primary event in renal cell oxalate toxicity. Kidney Int 66:1890
Khan SR, Khan A, Byer KJ (2011) Temporal changes in the expression of mRNA of NADPH oxidase subunits in renal epithelial cells exposed to oxalate or calcium oxalate crystals. Nephrol Dial Transplant 26:1778
Li N, Yi FX, Spurrier JL et al (2002) Production of superoxide through NADH oxidase in thick ascending limb of Henle’s loop in rat kidney. Am J Physiol Renal Physiol 282:F1111
Geiszt M, Kopp JB, Varnai P et al (2000) Identification of renox, an NAD(P)H oxidase in kidney. Proc Natl Acad Sci USA 97:8010
Hanna IR, Taniyama Y, Szocs K et al (2002) NAD(P)H oxidase-derived reactive oxygen species as mediators of angiotensin II signaling. Antioxid Redox Signal 4:899
Wilcox CS, Welch WJ (2001) Oxidative stress: cause or consequence of hypertension. Exp Biol Med (Maywood) 226:619
Shiose A, Kuroda J, Tsuruya K et al (2001) A novel superoxide-producing NAD(P)H oxidase in kidney. J Biol Chem 276:1417
Thamilselvan V, Menon M, Thamilselvan S (2009) Oxalate-induced activation of PKC-alpha and -delta regulates NADPH oxidase-mediated oxidative injury in renal tubular epithelial cells. Am J Physiol Renal Physiol 297:F1399
Thamilselvan V, Menon M, Thamilselvan S (2011) Selective Rac1 inhibition protects renal tubular epithelial cells from oxalate-induced NADPH oxidase-mediated oxidative cell injury. Urol Res [Epub ahead of print]
Zuo J, Khan A, Glenton PA et al (2011) Effect of NADPH oxidase inhibition on the expression of kidney injury molecule and calcium oxalate crystal deposition in hydroxy-l-proline-induced hyperoxaluria in the male Sprague-Dawley rats. Nephrol Dial Transplant 26:1785
Wassmann S, Laufs U, Muller K et al (2002) Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 22:300
Tsujihata M, Momohara C, Yoshioka I et al (2008) Atorvastatin inhibits renal crystal retention in a rat stone forming model. J Urol 180:2212
Toblli JE, Ferder L, Stella I et al (2001) Protective role of enalapril for chronic tubulointerstitial lesions of hyperoxaluria. J Urol 166:275
Toblli JE, Ferder L, Stella I et al (2002) Effects of angiotensin II subtype 1 receptor blockade by losartan on tubulointerstitial lesions caused by hyperoxaluria. J Urol 168:1550
Umekawa T, Hatanaka Y, Kurita T et al (2004) Effect of angiotensin II receptor blockage on osteopontin expression and calcium oxalate crystal deposition in rat kidneys. J Am Soc Nephrol 15:635
Khan SR, Shevock PN, Hackett RL (1992) Acute hyperoxaluria, renal injury and calcium oxalate urolithiasis. J Urol 147:226
de Bruijn WC, Boeve ER, van Run PR et al (1995) Etiology of calcium oxalate nephrolithiasis in rats. I. Can this be a model for human stone formation? Scanning Microsc 9:103
de Water R, Noordermeer C, van der Kwast TH et al (1999) Calcium oxalate nephrolithiasis: effect of renal crystal deposition on the cellular composition of the renal interstitium. Am J Kidney Dis 33:761
McKee MD, Nanci A, Khan SR (1995) Ultrastructural immunodetection of osteopontin and osteocalcin as major matrix components of renal calculi. J Bone Miner Res 10:1913
Umekawa T, Tsuji H, Uemura H et al (2009) Superoxide from NADPH oxidase as second messenger for the expression of osteopontin and monocyte chemoattractant protein-1 in renal epithelial cells exposed to calcium oxalate crystals. BJU Int 104:115
Rashed T, Menon M, Thamilselvan S (2004) Molecular mechanism of oxalate-induced free radical production and glutathione redox imbalance in renal epithelial cells: effect of antioxidants. Am J Nephrol 24:557
Koul HK, Menon M, Chaturvedi LS et al (2002) COM crystals activate the p38 mitogen-activated protein kinase signal transduction pathway in renal epithelial cells. J Biol Chem 277:36845
Chaturvedi LS, Koul S, Sekhon A et al (2002) Oxalate selectively activates p38 mitogen-activated protein kinase and c-Jun N-terminal kinase signal transduction pathways in renal epithelial cells. J Biol Chem 277:13321
Toblli JE, Cao G, Casas G et al (2005) NF-kappaB and chemokine-cytokine expression in renal tubulointerstitium in experimental hyperoxaluria. Role of the renin–angiotensin system. Urol Res 33:358
Jonassen JA, Cao LC, Honeyman T et al (2003) Mechanisms mediating oxalate-induced alterations in renal cell functions. Crit Rev Eukaryot Gene Expr 13:55
Umekawa T, Chegini N, Khan SR (2002) Oxalate ions and calcium oxalate crystals stimulate MCP-1 expression by renal epithelial cells. Kidney Int 61:105
Umekawa T, Iguchi M, Uemura H et al (2006) Oxalate ions and calcium oxalate crystal-induced up-regulation of osteopontin and monocyte chemoattractant protein-1 in renal fibroblasts. BJU Int 98:656
Iida S, Peck AB, Byer KJ et al (1999) Expression of bikunin mRNA in renal epithelial cells after oxalate exposure. J Urol 162:1480
Iida S, Peck AB, Johnson-Tardieu J et al (1999) Temporal changes in mRNA expression for bikunin in the kidneys of rats during calcium oxalate nephrolithiasis. J Am Soc Nephrol 10:986
Grewal JS, Tsai JY, Khan SR (2005) Oxalate-inducible AMBP gene and its regulatory mechanism in renal tubular epithelial cells. Biochem J 387:609
Moriyama MT, Glenton PA, Khan SR (2001) Expression of inter-alpha inhibitor related proteins in kidneys and urine of hyperoxaluric rats. J Urol 165:1687
Suzuki K, Tanaka T, Miyazawa K et al (1999) Gene expression of prothrombin in human and rat kidneys: basic and clinical approach. J Am Soc Nephrol 10(Suppl 14):S408
Lieske JC, Spargo BH, Toback FG (1992) Endocytosis of calcium oxalate crystals and proliferation of renal tubular epithelial cells in a patient with type 1 primary hyperoxaluria. J Urol 148:1517
Mandell I, Krauss E, Millan JC (1980) Oxalate-induced acute renal failure in Crohn’s disease. Am J Med 69:628
Wharton R, D’Agati V, Magun AM et al (1990) Acute deterioration of renal function associated with enteric hyperoxaluria. Clin Nephrol 34:116
Whitworth JA (2003) 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 21:1983
Moritz AR, Oldt MR (1937) Arteriolar sclerosis in hypertensive and non-hypertensive individuals. Am J Pathol 13:679
Kimmelstiel P, Wilson C (1936) Benign and malignant hypertension and nephrosclerosis: a clinical and pathological study. Am J Pathol 12:45
Johnson RJ, Feig DI, Nakagawa T et al (2008) Pathogenesis of essential hypertension: historical paradigms and modern insights. J Hypertens 26:381
Montecucco F, Pende A, Quercioli A et al (2010) Inflammation in the pathophysiology of essential hypertension. J Nephrol 24:23
Rodriguez-Iturbe B, Franco M, Tapia E et al (2011) Renal inflammation, autoimmunity and salt-sensitive hypertension. Clin Exp Pharmacol Physiol [Epub ahead of print]
Rodriguez-Iturbe B, Vaziri ND, Johnson RJ (2008) Inflammation, angiotensin II, and hypertension. Hypertension 52:e135 (author reply e136)
Rodriguez-Iturbe B, Vaziri ND, Herrera-Acosta J et al (2004) Oxidative stress, renal infiltration of immune cells, and salt-sensitive hypertension: all for one and one for all. Am J Physiol Renal Physiol 286:F606
Stefanadi E, Tousoulis D, Androulakis ES et al (2010) Inflammatory markers in essential hypertension: potential clinical implications. Curr Vasc Pharmacol 8:509
Briones AM, Touyz RM (2010) Oxidative stress and hypertension: current concepts. Curr Hypertens Rep 12:135
Nistala R, Whaley-Connell A, Sowers JR (2008) Redox control of renal function and hypertension. Antioxid Redox Signal 10:2047
Bautista LE, Lopez-Jaramillo P, Vera LM et al (2001) Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens 19:857
Chrysohoou C, Panagiotakos DB, Pitsavos C et al (2004) Adherence to the Mediterranean diet attenuates inflammation and coagulation process in healthy adults: The ATTICA Study. J Am Coll Cardiol 44:152
Sesso HD, Buring JE, Rifai N et al (2003) C-reactive protein and the risk of developing hypertension. JAMA 290:2945
Kurata M, Okura T, Watanabe S et al (2006) Osteopontin and carotid atherosclerosis in patients with essential hypertension. Clin Sci (Lond) 111:319
Stumpf C, John S, Jukic J et al (2005) Enhanced levels of platelet P-selectin and circulating cytokines in young patients with mild arterial hypertension. J Hypertens 23:995
Wilcox CS (2002) Reactive oxygen species: roles in blood pressure and kidney function. Curr Hypertens Rep 4:160
O’Connor PM, Cowley AW Jr (2010) Modulation of pressure-natriuresis by renal medullary reactive oxygen species and nitric oxide. Curr Hypertens Rep 12:86
Ignarro LJ, Napoli C, Loscalzo J (2002) Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview. Circ Res 90:21
Armas-Padilla MC, Armas-Hernandez MJ, Sosa-Canache B et al (2007) Nitric oxide and malondialdehyde in human hypertension. Am J Ther 14:172
Rodriguez-Iturbe B, Romero F, Johnson RJ (2007) Pathophysiological mechanisms of salt-dependent hypertension. Am J Kidney Dis 50:655
Chabrashvili T, Tojo A, Onozato ML et al (2002) Expression and cellular localization of classic NADPH oxidase subunits in the spontaneously hypertensive rat kidney. Hypertension 39:269
Schnackenberg CG, Welch WJ, Wilcox CS (1998) Normalization of blood pressure and renal vascular resistance in SHR with a membrane-permeable superoxide dismutase mimetic: role of nitric oxide. Hypertension 32:59
Zalba G, Beaumont FJ, San Jose G et al (2000) Vascular NADH/NADPH oxidase is involved in enhanced superoxide production in spontaneously hypertensive rats. Hypertension 35:1055
Grote K, Ortmann M, Salguero G et al (2006) Critical role for p47phox in renin–angiotensin system activation and blood pressure regulation. Cardiovasc Res 71:596
Landmesser U, Cai H, Dikalov S et al (2002) Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension 40:511
Zhou MS, Hernandez Schulman I, Pagano PJ et al (2006) Reduced NAD(P)H oxidase in low renin hypertension: link among angiotensin II, atherogenesis, and blood pressure. Hypertension 47:81
Tian N, Moore RS, Phillips WE et al (2008) NADPH oxidase contributes to renal damage and dysfunction in Dahl salt-sensitive hypertension. Am J Physiol Regul Integr Comp Physiol 295:R1858
Taylor NE, Glocka P, Liang M et al (2006) NADPH oxidase in the renal medulla causes oxidative stress and contributes to salt-sensitive hypertension in Dahl S rats. Hypertension 47:692
Kanwar YS, Sun L, Xie P et al (2011) A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu Rev Pathol 6:395
Navarro-Gonzalez JF, Mora-Fernandez C, Muros de Fuentes M et al (2011) Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol 7:327
Steckelings UM, Rompe F, Kaschina E et al (2009) The evolving story of the RAAS in hypertension, diabetes and CV disease: moving from macrovascular to microvascular targets. Fundam Clin Pharmacol 23:693
Matheson A, Willcox MD, Flanagan J et al (2010) Urinary biomarkers involved in type 2 diabetes: a review. Diabetes Metab Res Rev 26:150
Okonogi H, Nishimura M, Utsunomiya Y et al (2001) Urinary type IV collagen excretion reflects renal morphological alterations and type IV collagen expression in patients with type 2 diabetes mellitus. Clin Nephrol 55:357
Giacco F, Brownlee M (2010) Oxidative stress and diabetic complications. Circ Res 107:1058
Kakehi T, Yabe-Nishimura C (2008) NOX enzymes and diabetic complications. Semin Immunopathol 30:301
Chung SS, Ho EC, Lam KS et al (2003) Contribution of polyol pathway to diabetes-induced oxidative stress. J Am Soc Nephrol 14:S233
Asaba K, Tojo A, Onozato ML et al (2005) Effects of NADPH oxidase inhibitor in diabetic nephropathy. Kidney Int 67:1890
Etoh T, Inoguchi T, Kakimoto M et al (2003) Increased expression of NAD(P)H oxidase subunits, NOX4 and p22phox, in the kidney of streptozotocin-induced diabetic rats and its reversibility by interventive insulin treatment. Diabetologia 46:1428
Manea A (2010) NADPH oxidase-derived reactive oxygen species: involvement in vascular physiology and pathology. Cell Tissue Res 342:325
Brown BG, Zhao XQ, Chait A et al (2001) Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345:1583
Touyz RM (2003) Reactive oxygen species in vascular biology: role in arterial hypertension. Expert Rev Cardiovasc Ther 1:91
Manea A, Manea SA, Gafencu AV et al (2007) Regulation of NADPH oxidase subunit p22(phox) by NF-κB in human aortic smooth muscle cells. Arch Physiol Biochem 113:163
Stefanadi E, Tousoulis D, Papageorgiou N et al (2010) Inflammatory biomarkers predicting events in atherosclerosis. Curr Med Chem 17:1690
De Rosa S, Cirillo P, Paglia A et al (2010) Reactive oxygen species and antioxidants in the pathophysiology of cardiovascular disease: does the actual knowledge justify a clinical approach? Curr Vasc Pharmacol 8:259
Rivera J, Sobey CG, Walduck AK et al (2010) Nox isoforms in vascular pathophysiology: insights from transgenic and knockout mouse models. Redox Rep 15:50
Drummond GR, Selemidis S, Griendling KK et al (2011) Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov 10:453
Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259:87
Kern PA, Ranganathan S, Li C et al (2001) Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280:E745
Pradhan AD, Manson JE, Rifai N et al (2001) C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286:327
Furukawa S, Fujita T, Shimabukuro M et al (2004) Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114:1752
Soares AF, Guichardant M, Cozzone D et al (2005) Effects of oxidative stress on adiponectin secretion and lactate production in 3T3–L1 adipocytes. Free Radic Biol Med 38:882
Silver AE, Beske SD, Christou DD et al (2007) Overweight and obese humans demonstrate increased vascular endothelial NAD(P)H oxidase-p47(phox) expression and evidence of endothelial oxidative stress. Circulation 115:627
Otani H (2011) Oxidative stress as pathogenesis of cardiovascular risk associated with metabolic syndrome. Antioxid Redox Signal 15:1911
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Khan, S.R. Is oxidative stress, a link between nephrolithiasis and obesity, hypertension, diabetes, chronic kidney disease, metabolic syndrome?. Urol Res 40, 95–112 (2012). https://doi.org/10.1007/s00240-011-0448-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00240-011-0448-9